Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | CASP1 | P29466 | 5/20 | 0.69 |
| ▸ | CASP7 | P55210 | 5/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | BACE1 | P56817 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30397364 | 0.91 | ABCB1 (0.79) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL25235022 | 0.91 | ABCB1 (0.79) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL1977887 | 0.87 | MAPT (0.58) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL1422017 | 0.85 | MAPT (0.76) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL1973404 | 0.84 | MAPT (0.58) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL31675757 | 0.82 | ABCB1 (1.00) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL4650613 | 0.82 | ABCB1 (1.00) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL4648874 | 0.81 | ABCG2 (0.82) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL30667444 | 0.81 | MAPT (1.00) | ABCB1MAPTKDM4ECYP3A4CASP1 | |
| SCHEMBL24614952 | 0.81 | ABCG2 (1.00) | ABCB1MAPTKDM4ECYP3A4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | ABCB1 2178/4885MAPT 243/4885KDM4E 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.